Skip to main content

Warnex to Acquire Genetic Testing Firm PRO-DNA for $2M

NEW YORK, April 25 (GenomeWeb News) - Canadian firm Warnex said today that it has agreed in principle to acquire genetic testing service provider PRO-DNA Diagnostic for $2 million.


The purchase price is divided into $1.2 million in cash, approximately $200,000 to $300,000 in working capital adjustments, and $500,000 payable in common shares of Warnex, the company said.


"The acquisition of PRO-DNA will mark our entry into the field of human genetics testing and pharmacogenomics," Mark Busgang, president and CEO of Warnex, said in a statement.


PRO-DNA had $870,000 in revenues in its last fiscal year and is expected to be immediately accretive to earnings, Warnex said. It will operate as a division of Warnex Medical Laboratories and will be relocated from Montreal to the Warnex facilities in Laval, Quebec.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.